Sert, F., & Ulucan, O. (2025). Mast cells drive ferroptosis in gastric tumors as key players in the tumor immune microenvironment. OMICS: A Journal of Integrative Biology, 29(9), 429–441.

Ulucan, O. (2025). Discovery of potential PD-1 and PD-L1 interaction inhibitors using combined molecular modeling approaches. Adıyaman University Journal of Science, 15(1), 17–34.

Ulucan, O. (2024). Expanding beyond genetic subtypes in B-cell acute lymphoblastic leukemia: A pathway-based stratification of patients for precision oncology. OMICS: A Journal of Integrative Biology, 28(9), 470–477.

Gelmez, P., Karakoç, T. E., & Ulucan, O. (2024). Autism spectrum disorder and atypical brain connectivity: Novel insights from brain connectivity-associated genes by combining random forest and support vector machine algorithm. OMICS: A Journal of Integrative Biology, 28(11), 563–572.

Eyilcim, Ö., Günay, F., Ng, Y. Y., Ulucan Acan, O., Turgut, Z., & Günkara, Ö. T. (2024). Design, synthesis, biological evaluation and molecular docking studies of a new series of maleimide derivatives. ChemistryOpen, 13(12), e202400058.

Eyilcim, Ö., Günay, F., Günkara, Ö. T., Ng, Y. Y., Ulucan, O., & Erden, İ. (2023). Design and synthesis of novel 1,2,3,4-tetrazines as new anti-leukemia cancer agents. Chemical Biology & Drug Design, 102(5), 1186–1201.

Günay, F., Balta, S., Ng, Y. Y., Ulucan, O., Turgut, Z., & Günkara, O. T. (2022). Synthesis, molecular modeling, and biological evaluation of novel imatinib derivatives as anticancer agents. Turkish Journal of Chemistry.

Cakir, A., Tuncer, M., Taymaz-Nikerel, H., & Ulucan, O. (2021). Side effect prediction based on drug-induced gene expression profiles and random forest with iterative feature selection. The Pharmacogenomics Journal, 21(6), 673–681.

Shanak, S., Ulucan, O., & Helms, V. (2017). Methylation-targeted specificity of the DNA binding proteins R. DpnI and MeCP2 studied by molecular dynamics simulations. Journal of Molecular Modeling, 23(5), 152.

Hochscherf, J., Lindenblatt, D., Steinkrüger, M., Yoo, E., Ulucan, O., Herzig, S., Issinger, O.-G., Helms, V., Götz, C., Neundorf, I., & others. (2015). Development of a high-throughput screening-compatible assay to identify inhibitors of the CK2α/CK2β interaction. Analytical Biochemistry, 468, 4–14.

Ulucan, O., & Helms, V. (2015). How hydrophilic proteins form nonspecific complexes. The Journal of Physical Chemistry B, 119(33), 10524–10530.

Ulucan, O., Jaitly, T., & Helms, V. (2014). Energetics of hydrophilic protein–protein association and the role of water. Journal of Chemical Theory and Computation, 10(8), 3512–3524.

Tretter, T., Pereira, F. P., Ulucan, O., Helms, V., Allan, S., Kalies, K.-U., & Römisch, K. (2013). ERAD and protein import defects in a Sec61 mutant lacking ER-lumenal loop 7. BMC Cell Biology, 14(1), 56.

Walter, P., Ulucan, O., Metzger, J., & Helms, V. (2012). Bioinformatics of protein–protein interfaces and small molecule effectors. Current Bioinformatics, 7(2), 159–172.

Ulucan, O., Eyrisch, S., & Helms, V. (2012). Druggability of dynamic protein–protein interfaces. Current Pharmaceutical Design, 18(30), 4599–4606.

Schäuble, N., Lang, S., Jung, M., Cappel, S., Schorr, S., Ulucan, Ö., Linxweiler, J., Dudek, J., Blum, R., Helms, V., & others. (2012). BiP-mediated closing of the Sec61 channel limits Ca2+ leakage from the ER. The EMBO Journal, 31(15), 3282.

Ulucan, O., Keskin, O., Erman, B., & Gürsoy, A. (2011). A comparative molecular dynamics study of methylation state specificity of JMJD2A. PLoS ONE, 6(9), e24664.